AKT1 and cancer: Until today, although several PI3K/Akt/mTOR inhibitors have been studied in clinical trials in cancer patients, only a few of them (e.g., temsirolimus, everolimus, copanlisib) have been approved for clinical use in the treatment of different cancers [204].